Chemical formula: C₄H₄FN₃O Molecular mass: 129.093 g/mol PubChem compound: 3366
Flucytosine interacts in the following cases:
In animal studies, flucytosine and one of its metabolites (5-fluorouracil) showed reproductive toxicity (teratogenicity and embyrotoxicity).
In humans, flucytosine crosses the placenta. There are very limited data on use of flucytosine in pregnant women. Therefore harmful impact on the embryo/foetus cannot be excluded, especially during the first trimester. Consequently Ancotil should not be used during pregnancy and in women of childbearing potential not using contraception unless strictly necessary in case of life-threatening infections and lack of an effective alternative treatment.
There are no data on the excretion of flucytosine in human milk. Breastfeeding is contraindicated during flucytosine treatment.
Flucytosine is partially metabolised into 5-fluorouracil, which is genotoxic and considered as a potential human teratogen. Females of childbearing potential under treatment must use effective contraceptive during treatment and for one month after treatment. Male patients (or their female partners of childbearing potential) must use effective contraception during treatment and for three months after treatment.
Not applicable.
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
